Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT. Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol 2009; 15(43): 5465-5471 [PMID: 19916178 DOI: 10.3748/wjg.15.5465]
Corresponding Author of This Article
Ming-Tsang Wu, MD, ScD, Department of Family Medicine, Kaohsiung Medical University Hospital, 100 Shih-Chuan 1st Road, Kaohsiung 807, Taiwan, China. 960021@ms.kmuh.org.tw
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
I-Chen Wu, Deng-Chyang Wu, Fang-Jung Yu, Chao-Hung Kuo, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, China
Deng-Chyang Wu, Jaw-Yuan Wang, Chao-Hung Kuo, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China
Jaw-Yuan Wang, Division of Gastrointestinal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, China
Sheau-Fang Yang, Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, China
Chao-Ling Wang, Ming-Tsang Wu, Graduate Institute of Occupational Safety and Health, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China
Chao-Ling Wang, Department of Preventive Medicine, Kaohsiung Medical University Hospital, Kaoshiung 807, Taiwan, China
Ming-Tsang Wu, Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, China
ORCID number: $[AuthorORCIDs]
Author contributions: Wu IC, Wu DC and Wu MT participated in the analysis of data, designed and conducted the research and wrote the manuscript; Yang SF participated in the laboratory analysis; Yu FJ, Wang JY, Kuo CH and Wang CL participated in the collection of study subjects.
Supported by Grants From Kaohsiung Medical University Hospital, 97-ND-006, the National Science Council, NSC 97-2314-B-037-018, NSC 98-2314-B-037-004, and the Department of Health, Taiwan
Correspondence to: Ming-Tsang Wu, MD, ScD, Department of Family Medicine, Kaohsiung Medical University Hospital, 100 Shih-Chuan 1st Road, Kaohsiung 807, Taiwan, China. 960021@ms.kmuh.org.tw
Received: September 1, 2009 Revised: October 9, 2009 Accepted: October 16, 2009 Published online: November 21, 2009
Abstract
AIM: To explore the role of Helicobacter pylori (H pylori) infection on the risk of digestive tract cancers.
METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection. Two hospital- and one community-based control groups were used for the comparisons. H pylori seropositivity was determined by an enzyme linked immunosorbent assay method against H pylori IgG.
RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups. Similar results were not found in cancers of the oral cavity and colon.
CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
Citation: Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT. Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol 2009; 15(43): 5465-5471
It is widely accepted that chronic Helicobacter pylori (H pylori) infection, especially cytotoxin-associated gene A (CagA)-positive strains, causes non-cardiac gastric carcinoma via the intestinal metaplasia-carcinoma sequence[1,2]. However, there is debate in regard to the association between
H pylori infection and gastric cardia adenocarcinoma. Most studies in Asian countries[3-5] have indicated an increased risk of cardia cancer in H pylori-infected subjects, while those in Western countries have reported a protective role of H pylori[6] or a negative association[7-9] between these two.
Recently, cumulative evidence has indicated that H pylori infection plays a protective role in the development of reflux esophagitis[10,11] and esophageal adenocarcinoma (EA)[6,8,12,13]. In contrast, the relationship between H pylori infection and esophageal squamous cell carcinoma (SCC) is still inconclusive[8,14-17]. Very few studies have examined the role of H pylori infection on colon and oral cancers. Therefore, we aim to expand our esophageal SCC cases and to examine the relationship between H pylori infection and the risk of oral SCC, gastric cancer, especially gastric cardia adenocarcinoma and colon cancer, in a Taiwanese population.
MATERIALS AND METHODS
Selection of cases and controls
This was a hospital-based case-control study design. Three hundred and seventeen newly pathologically proven ESCC patients (301 males and 16 females) were recruited from two medical centers in the Kaohsiung metropolitan area in southern Taiwan, including the Kaohsiung Medical University Hospital (KMUH) and the Kaohsiung Veterans General Hospital (KVGH) between 2000 and 2007. The detailed information was described elsewhere[18]. Patients with newly pathologically proven oral SCC (n = 199), gastric (n = 196) and colon adenocarcinoma (n = 240) were recruited from the KMUH in the same period.
The first hospital-based control group was recruited from the Department of Preventive Medicine in these two hospitals and matched with each esophageal SCC patient (case:control = 1:1-4) by gender, age (within a 4 year age difference) and hospitalization (within 4 wk after each case was identified). In this study, we randomly selected 1 out of 1-4 matched controls (n = 305, 289 males and 16 females) for each case to investigate the status of H pylori infection[19]. Twelve cases did not have suitable controls. In order to examine the different prevalence of H pylori infection from different areas or different sources of selection, we included another two comparison groups, defined as the second hospital-based control group and the community-based control group, in this study. The second hospital-based control group (n = 403, 374 males and 29 females) were originally used for the esophageal cancer study in National Taiwan University Hospital (NTUH) in Taipei[20]. They were cancer-free, had visited for a health check-up in NTUH, and had enough stored serum specimens for testing H pylori status during the same period of this study. The community-based control group (n = 395, 204 males and 191 females) consisted of healthy subjects living in Kaohsiung who voluntarily participated in one large multi-year study of childhood neoplasms at the same period of this study[14,21]. The second hospital-based and the community-based control groups were not matched by age and gender with our esophageal SCC patients.
All subjects provided blood samples before any treatment or blood transfusion for H pylori seropositivity. For those with positive H pylori antibodies, CagA status was further examined using an enzyme immunoassay. The institutional review boards at NTUH and KMUH reviewed and approved this study, and all participants signed written sheets of informed consent.
Location of esophageal SCC and gastric adenocarcinoma
Lesions were classified with respect to their location in the upper, middle or lower third of the esophagus, described previously[22,23]. Gastric cardia adenocarcinomas were defined as a tumor centered within 3 cm distal to the gastroesophageal junction. There was no difficulty in distinguishing lower third esophageal cancer with cardia invasion from gastric cardia cancer extending to the lower esophagus, because SCC comprise more than 95% of esophageal cancers in Taiwan[24]. Cardia adenocarcinoma was classified as being of gastric origin, if Barrett’s esophagus was not detected in the adjacent tissue.
H pylori serology and CagA status
Non-heparinized whole blood was collected and serum was isolated and stored at -70°C for subsequent analysis. A commercially available immunochromatographic screening test (Chembio H pylori STAT-PAK, Chembio Diagnostic System, Inc., Medford, NY, USA) utilizing a combination of H pylori antigen coated particles and anti-human IgG was used to qualitatively and selectively detect H pylori antibodies in serum[14]. According to the manufacturer’s instructions, the sensitivity and specificity of STAT-PAK were 94% and 98%, respectively. Final readings were recorded after verification by at least two research technicians blinded to the status of cases and controls.
A commercial kit, Helori CTX IgG (ravo Diagnostika GmbH, Freiburg, Germany), was used to detect the IgG antibodies against serum CagA by enzyme immunoassay. The average optical density (A) values of subject specimens, blank, negative and positive controls were calculated. The A of negative and positive controls must be always < 0.100 and > 0.800, respectively, in each set of samples. The concentration of each sample was expressed as units obtained from the formula: sample A× calibrator value (units)/calibrator A Based on guidelines set forth by the manufacturer, we set negative and positive cutoff points for each concentration as < 5 and ≥ 5 units, respectively. The research technicians were also blinded to the status of cases and controls.
Statistical analysis
Multiple logistic regression models were used to examine the association between H pylori infection (seropositivity by STAT-PAK) and esophageal SCC risk using each of three control groups as a basis of comparison before and after adjusting for other covariates, including age (continuous), gender, educational levels (≤ primary school, junior high and high school, and > high school), cigarette smoking, alcohol drinking and betel nut chewing. Information about betel nut chewing was not available in the community control, so it was not evaluated in the regression models when the community control was used as the control group. The data were analyzed using the SAS statistical package; all P-values were two-sided.
RESULTS
Distribution of demographic variables and substance use for cancer cases and controls is summarized in Table 1. The majority of oral and esophageal SCC patients were male, and more than half of all cancer patients had an educational level of primary school or below. The ratio of women to men among the esophageal SCC was 3.5% (6/173) in KVGH, which is slightly lower, but not significantly different, than that in KMUH (6.9%, 10/144, P-value = 0.18). The mean age of the community control group (40.2 ± 6.2 years) was about 20 years younger than the other two control groups.
Table 1 Demographic characteristics of digestive tract cancer patients and controls n (%).
Cancer
Control
Oral SCC
Esophageal SCC
Gastric adenocarcinoma
Colon adenocarcinoma
1st hospital-based control
2nd hospital-based control
Community-based control
n
199
317
196
240
305
403
395
Age mean ± SD
50.6 ± 9.9
58.3 ± 11.6
63.2 ± 13.5
64.5 ± 12.7
57.1 ± 11.4
60.0 ± 10.2
40.2 ± 6.2
(min, med, max)
(26, 50, 78)
(34, 58, 86)
(22, 65, 91)
(24, 66, 89)
(34, 57, 82)
(39, 60, 84)
(30, 40, 58)
Sex
Male
188 (90.5)
301 (95.0)
123 (62.8)
139 (57.9)
289 (94.8)
374 (92.8)
204 (51.6)
Female
11 (5.5)
16 (5.0)
73 (37.2)
101 (42.1)
16 (5.2)
29 (7.2)
191 (48.4)
Educational level
≤ primary school
117 (58.8)
176 (55.5)
118 (60.2)
133 (55.4)
78 (25.6)
162 (40.2)
41 (10.4)
Junior high & high school
76 (38.2)
120 (37.9)
53 (27.0)
72 (30.0)
93 (30.5)
76 (18.9)
241 (61.0)
> high school
6 (3.0)
21 (6.6)
25 (12.8)
35 (14.6)
134 (43.9)
165 (40.9)
113 (28.6)
Cigarette smoking
No
32 (16.1)
39 (12.3)
101 (51.5)
143 (59.6)
168 (55.1)
248 (61.5)
283 (71.6)
Yes
167 (83.9)
278 (87.7)
95 (48.5)
97 (40.4)
137 (44.9)
155 (38.5)
112 (28.4)
Alcohol consumption
No
64 (32.2)
60 (18.9)
145 (74.0)
193 (80.4)
215 (70.5)
288 (71.5)
298 (75.4)
Yes
135 (67.8)
257 (81.1)
51 (26.0)
47 (19.6)
90 (29.5)
115 (28.5)
97 (24.6)
Betel quid chewing
No
29 (14.6)
149 (47.0)
171 (87.2)
213 (88.8)
280 (91.8)
381 (94.5)
-
Yes
170 (85.4)
168 (53.0)
25 (12.8)
27 (11.2)
25 (8.2)
22 (5.5)
-
The H pylori seropositivity in esophageal SCC patients was 35.3%, which was consistently lower than those in the three controls (40.5%-59.3%) (Table 2). The seropositivity of H pylori among the ESCC patients was similar in those two hospitals: 36.1% (KMUH 53/147) and 34.7% (KVGH 59/170) (data not shown). In contrast, H pylori seropositivity in gastric adenocarcinoma patients (71.4%) was higher than that in all three control groups. H pylori seropositivity in gastric cardia and non-cardia adenocarcinoma patients was similar (Table 2). In addition, the prevalence of CagA-positive subjects among H pylori-infected cancer cases was 71.6%-85.9%, similar to that among H pylori-infected controls (76.8%-89.0%).
Table 2 Serum status of H pylori and CagA in cancer patients and control n (%).
In multivariate analyses, there was still a significantly inverse association between H pylori seropositivity and esophageal SCC (AOR: 0.315-0.472, all P-values < 0.05). In the multivariate analyses of esophageal SCC and 1st hospital control, besides the significant protective effect of H pylori, we found that cigarette smoking (AOR = 2.608, 95% CI: 1.540-4.414), alcohol consumption (AOR = 5.078, 95% CI: 3.130-8.240), and betel nut chewing (AOR = 5.142, 95% CI: 2.916-9.065) are still the significant risk factors for esophageal SCC. However, we did not see any significant interaction between H pylori and any of those substances (tobacco, alcohol, and betel nut) in the multivariate analyses.
H pylori infection was positively related to gastric adenocarcinoma, including the cardia (AOR: 1.636-3.060; all P-values < 0.05), in comparison to all three control groups, after adjusting for other co-variates (Table 3). Oral SCC was found to have a significantly inverse association with H pylori infection (AOR = 0.378, 95% CI: 0.190-0.751), when compared with the 2nd hospital-based control group, but not the other two. H pylori infection was not significantly associated with colon cancer, compared with all three control groups.
Table 3 Association between H pylori infection and cancer risks.
After expanding the case number of esophageal SCC patients, we still found an inverse association between H pylori seropositivity and esophageal SCC when compared to different control groups. Conflicting results were reported in the previous two prevalence studies about the relationship between the two in Sweden[8,17]. One nationwide case-control study conducted by Ye et al[8] used enzyme-linked immunosorbent assay (ELISA) to detect both serum H pylori and CagA antibodies in 85 esophageal SCC patients and 499 controls in Sweden. Initially, they did not find any significant association between H pylori seropositivity and esophageal SCC risk (AOR = 0.9, 95% CI: 0.5-1.6). Thus, the authors further categorized the study subjects based on both statuses of H pylori and CagA seropositivity. They found subjects with negative H pylori but positive CagA, to have a significant 3.0-fold risk of developing esophageal SCC, compared with those who were found to be negative for both[8]. But the insignificant finding was noted in the group of both positive H pylori and CagA patients (AOR = 1.6, 95% CI: 0.8-3.3). That was a post-hoc statistical analysis, so the preliminary finding is a warranty for further confirmation. Siman et al[17] updated their nested case-control study and found neither H pylori (OR = 0.44, 95% CI: 0.15-1.2) nor CagA seropositivity (OR = 2.0, 95% CI: 0.24-infinity) was significantly associated with esophageal SCC risk (n = 37). Recently, two studies were conducted in two major endemic areas in China-Huaian City[15] and Linxian[16]. The population-based case-control study in Huaian (case number 107) showed those with positive findings for H pylori antibody to be at 3-fold risk of developing esophageal SCC (AOR = 3.19, 95% CI: 1.11-9.15)[15]. But, in the case-cohort study including 335 ESCC patients in Linxian, no association was found between esophageal SCC risk and positive finding for antibodies to either H pylori (Hazard ratio = 1.17, 95% CI: 0.88-1.57) or CagA (Hazard ratio = 1.08, 95% CI: 0.80-1.47)[16]. In these two areas, the predominant risk factors for ESCC were diet and nutrition, instead of cigarette smoking and alcohol consumption mostly found in Western countries and Taiwan. The Linxian research group suggested the difference in risk factors for esophageal SCC in different areas may affect the relationship between H pylori and esophageal SCC[16].
In Taiwan, about 95% H pylori strain is CagA positive[25]. This study has shown that subjects with positive H pylori serology have > 85% CagA+ strains in both esophageal SCC patients and controls, suggesting using IgG serology to measure H pylori infection can represent the CagA+ strains in Taiwan. The relatively low seroprevalence of H pylori infection in the community control group may be due to younger age (average age = 40.2 years), compared to those in the two hospital-based control groups (average age = 57.1 and 60.0 years).
The exact mechanism by which H pylori infection affects the development of EA and esophageal SCC is still puzzling. The strongest risk factor of distal EA is Barrett’s esophagus, a condition secondary to long-term gastroesophageal reflux disease, and H pylori colonization may protect against Barrett’s esophagus[11,13,26]. Richter et al[27] also hypothesized that H pylori can prevent EA development through gastric atrophy and possibly by increased intragastric ammonia production. Ye et al[8] challenged this hypothesis by demonstrating an unaffected protective effect for EA after adjusting for gastric atrophy. However, they hypothesized that CagA+H pylori infection caused esophageal SCC through the pathway of gastric atrophy[8]. An atrophic stomach might enhance the overgrowth of bacteria and increase endogenous nitrosamines production, which causes esophageal SCC[28]. In contrast, another hypothesis is H pylori-induced gastric atrophy, which decreases intragastric acidity[14], might protect the lower esophageal mucosa from repeated injury by acid exposure, and thus decrease the esophageal SCC risk in an Asian population[29]. Another mechanism concerning the protective effect of H pylori infection on esophageal cancer risk directly involves apoptosis[30,31]. Jones et al[30] found significantly increasing apoptosis in OE33 Barrett’s-derived EA cells, but not in normal esophageal cells, after being treated with intact H pylori wild-type strains. Our in vitro study demonstrated similar apoptosis effect on esophageal SCC cells, but not in AGS cells, after being co-cultured with H pylori[31]. However, this proposed mechanism is still speculative and needs to be further verified.
The prevalence of H pylori infection in patients with cardia and non-cardia adenocarcinoma was about 70%, significantly higher than control subjects (about 56%), which was similar to the previous study done in China[4]. Fewer cardia cancer patients (n = 29) were noted in our study, but the prevalence of H pylori and CagA seropositivity was similar to that in non-cardia cancer patients. Previous studies have linked H pylori colonization to carditis and intestinal metaplasia in the cardia, indicating a role distinct from Barrett’s esophagus[32,33]. The subsites of gastric cancer were not well defined in some of the previous studies, but most researchers in Asian countries[3-5,34] supported at least a trend of positive association between H pylori seropositivity and proximal gastric cancer. On the contrary, observational studies in Western countries indicated no association[7-9] or inverse association[6] between H pylori seropositivity and cardia cancer. Further studies are needed to investigate the discrepancy of findings between Asian and Caucasian populations.
H pylori infection was not significantly associated with the risk of colon adenocarcinoma in this study. Hartwich et al[35] found a positive association between colon adenocarcinoma risk and H pylori seropositivity, especially CagA+ strains. However, there are also reports indicating no association between H pylori seroprevalence and colorectal neoplasia[36,37]. In addition, a recent report from Taiwan did not find any association between H pylori infection by the 13C-urea breath test and the risk of colon adenomatous polyp, which is the pre-cancer of colon adenocarcinoma[38].
The effect of H pylori infection on oral SCC risk has not yet been determined. Our study found conflicting results when H pylori infection status in three comparison controls was compared to that in oral cancer patients. Previous studies have shown that H pylori was detectable in the oral cavity by histopathologic diagnosis or polymerase chain reaction[39,40], but this bacterium may be present as a transient organism because of the difficulty of surviving in the oral cavity[41]. Thus, further studies are necessary to elucidate the relationship between H pylori infection and oral cancer risk.
Several limitations were present in this study: (1) The control group is mainly for the comparison of esophageal SCC, but not for other digestive cancers; (2) This is a cross-sectional case-control study design; the causal relationship may be not clearly elucidated; (3) Like other epidemiological studies[8,15-17], we only measured H pylori antibodies in human serum, which may not be representative for actual H pylori infection.
In summary, our study supports an inverse relationship between H pylori prevalence and esophageal SCC risk in Taiwan. In contrast, H pylori infection increases gastric adenocarcinoma risk, including the cardia and non-cardia. There is an inconsistent or negative association between H pylori infection and the risks of oral and colon cancers. The choice of the control groups in this study were mainly for the comparison of esophageal SCC, but not for other patient groups. Thus, the role of H pylori in digestive tract cancers, except esophageal SCC, in this study still requires further examination.
COMMENTS
Background
There is debate in regard to the association between Helicobacter pylori (H pylori) infection and gastric cardia adenocarcinoma. Recently, cumulative evidence has indicated that H pylori infection plays a protective role in the development of esophageal adenocarcinoma. In contrast, the relationship between H pylori infection and esophageal squamous cell carcinoma (SCC) is still inconclusive. Very few studies have examined the role of H pylori on colon and oral cancers.
Research frontiers
This study aimed to explore the role of H pylori infection on the risk of digestive tract cancers, including cancers of the oral cavity, esophagus, stomach, and colon.
Innovations and breakthroughs
H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric non-cardia and cardia adenocarcinoma.
Applications
Eradication of H pylori in all infected subjects should be cautious because H pylori might protect against other diseases, such as esophageal cancer.
Terminology
STAT-PAK assay for H pylori is an immunochromatographic screening test to detect H pylori IgG antibodies in serum; Helori CTX IgG kit is an enzyme immunoassay to detect CagA (the virulent protein of H pylori) IgG antibodies in serum.
Peer review
This is an important clinical observational study, indicating H pylori is not always a bad bug. Although H pylori can cause gastric non-cardia and cardia adenocarcinoma, it may protect against esophageal cancer.
Footnotes
Peer reviewer: Mark Bloomston, MD, FACS, Assistant Professor of Surgery, Division of Surgical Oncology, The Ohio State University, N924 Doan Hall,410W.10th Avenue, Columbus, OH 43082, United States
S- Editor Wang YR L- Editor O’Neill M E- Editor Ma WH
Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils.Gastroenterology. 1998;115:642-648.
[PubMed] [DOI][Cited in This Article: ]
Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma.N Engl J Med. 1991;325:1127-1131.
[PubMed] [DOI][Cited in This Article: ]
Limburg P, Qiao Y, Mark S, Wang G, Perez-Perez G, Blaser M, Wu Y, Zou X, Dong Z, Taylor P. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China.J Natl Cancer Inst. 2001;93:226-233.
[PubMed] [DOI][Cited in This Article: ]
Kikuchi S, Wada O, Nakajima T, Nishi T, Kobayashi O, Konishi T, Inaba Y. Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults.Cancer. 1995;75:2789-2793.
[PubMed] [DOI][Cited in This Article: ]
Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma.Cancer Res. 1998;58:588-590.
[PubMed] [DOI][Cited in This Article: ]
Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus.Int J Cancer. 2003;103:815-821.
[PubMed] [DOI][Cited in This Article: ]
Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyren O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia.J Natl Cancer Inst. 2004;96:388-396.
[PubMed] [DOI][Cited in This Article: ]
Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer.Gastroenterology. 2003;125:1636-1644.
[PubMed] [DOI][Cited in This Article: ]
Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.Gastroenterology. 1997;112:1442-1447.
[PubMed] [DOI][Cited in This Article: ]
Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study.Gut. 2008;57:727-733.
[PubMed] [DOI][Cited in This Article: ]
Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.Am J Gastroenterol. 2000;95:387-394.
[PubMed] [DOI][Cited in This Article: ]
de Martel C, Llosa AE, Farr SM, Friedman GD, Vogelman JH, Orentreich N, Corley DA, Parsonnet J. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma.J Infect Dis. 2005;191:761-767.
[PubMed] [DOI][Cited in This Article: ]
Wu DC, Wu IC, Lee JM, Hsu HK, Kao EL, Chou SH, Wu MT. Helicobacter pylori infection: a protective factor for esophageal squamous cell carcinoma in a Taiwanese population.Am J Gastroenterol. 2005;100:588-593.
[PubMed] [DOI][Cited in This Article: ]
Wang Z, Tang L, Sun G, Tang Y, Xie Y, Wang S, Hu X, Gao W, Cox SB, Wang JS. Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China.BMC Cancer. 2006;6:287.
[PubMed] [DOI][Cited in This Article: ]
Kamangar F, Qiao YL, Blaser MJ, Sun XD, Katki H, Fan JH, Perez-Perez GI, Abnet CC, Zhao P, Mark SD. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China.Br J Cancer. 2007;96:172-176.
[PubMed] [DOI][Cited in This Article: ]
Siman JH, Engstrand L, Berglund G, Forsgren A, Floren CH. Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma.Scand J Gastroenterol. 2007;42:933-940.
[PubMed] [DOI][Cited in This Article: ]
Lee CH, Wu DC, Lee JM, Wu IC, Goan YG, Kao EL, Huang HL, Chan TF, Chou SH, Chou YP. Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of the oesophagus in relation to tobacco smoking.Eur J Cancer. 2007;43:1188-1199.
[PubMed] [DOI][Cited in This Article: ]
Chen YJ, Chen C, Wu DC, Lee CH, Wu CI, Lee JM, Goan YG, Huang SP, Lin CC, Li TC. Interactive effects of lifetime alcohol consumption and alcohol and aldehyde dehydrogenase polymorphisms on esophageal cancer risks.Int J Cancer. 2006;119:2827-2831.
[PubMed] [DOI][Cited in This Article: ]
Wu MT, Lee YC, Chen CJ, Yang PW, Lee CJ, Wu DC, Hsu HK, Ho CK, Kao EL, Lee JM. Risk of betel chewing for oesophageal cancer in Taiwan.Br J Cancer. 2001;85:658-660.
[PubMed] [DOI][Cited in This Article: ]
Yu CL, Wang SF, Pan PC, Wu MT, Ho CK, Smith TJ, Li Y, Pothier L, Christiani DC. Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure.Am J Epidemiol. 2006;164:200-207.
[PubMed] [DOI][Cited in This Article: ]
Wu MT, Wu DC, Hsu HK, Kao EL, Lee JM. Relationship between site of oesophageal cancer and areca chewing and smoking in Taiwan.Br J Cancer. 2003;89:1202-1204.
[PubMed] [DOI][Cited in This Article: ]
Lee CH, Lee JM, Wu DC, Hsu HK, Kao EL, Huang HL, Wang TN, Huang MC, Wu MT. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan.Int J Cancer. 2005;113:475-482.
[PubMed] [DOI][Cited in This Article: ]
Yang JC, Wang TH, Wang HJ, Kuo CH, Wang JT, Wang WC. Genetic analysis of the cytotoxin-associated gene and the vacuolating toxin gene in Helicobacter pylori strains isolated from Taiwanese patients.Am J Gastroenterol. 1997;92:1316-1321.
[PubMed] [DOI][Cited in This Article: ]
Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?Gut. 2005;54 Suppl 1:i1-i5.
[PubMed] [DOI][Cited in This Article: ]
Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad.Am J Gastroenterol. 1998;93:1800-1802.
[PubMed] [DOI][Cited in This Article: ]
Houben GM, Stockbrugger RW. Bacteria in the aetio-pathogenesis of gastric cancer: a review.Scand J Gastroenterol Suppl. 1995;212:13-18.
[PubMed] [DOI][Cited in This Article: ]
Fujimori T, Kawamata H, Ichikawa K, Ono Y, Okura Y, Tomita S, Imura J. Pathological issues of gastric and lower esophageal cancer: helicobacter pylori infection and its eradication.J Gastroenterol. 2002;37 Suppl 13:28-33.
[PubMed] [DOI][Cited in This Article: ]
Peek RM Jr, Vaezi MF, Falk GW, Goldblum JR, Perez-Perez GI, Richter JE, Blaser MJ. Role of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia.Int J Cancer. 1999;82:520-524.
[PubMed] [DOI][Cited in This Article: ]
Goldblum JR, Vicari JJ, Falk GW, Rice TW, Peek RM, Easley K, Richter JE. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection.Gastroenterology. 1998;114:633-639.
[PubMed] [DOI][Cited in This Article: ]
Yuan JM, Yu MC, Xu WW, Cockburn M, Gao YT, Ross RK. Helicobacter pylori infection and risk of gastric cancer in Shanghai, China: updated results based upon a locally developed and validated assay and further follow-up of the cohort.Cancer Epidemiol Biomarkers Prev. 1999;8:621-624.
[PubMed] [DOI][Cited in This Article: ]
Hartwich A, Konturek SJ, Pierzchalski P, Zuchowicz M, Labza H, Konturek PC, Karczewska E, Bielanski W, Marlicz K, Starzynska T. Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer.Int J Colorectal Dis. 2001;16:202-210.
[PubMed] [DOI][Cited in This Article: ]
Siddheshwar RK, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of Helicobacter pylori in patients with colorectal polyps and colorectal carcinoma.Am J Gastroenterol. 2001;96:84-88.
[PubMed] [DOI][Cited in This Article: ]
Moss SF, Neugut AI, Garbowski GC, Wang S, Treat MR, Forde KA. Helicobacter pylori seroprevalence and colorectal neoplasia: evidence against an association.J Natl Cancer Inst. 1995;87:762-763.
[PubMed] [DOI][Cited in This Article: ]
Liou JM, Lin JW, Huang SP, Lin JT, Wu MS. Helicobacter pylori infection is not associated with increased risk of colorectal polyps in Taiwanese.Int J Cancer. 2006;119:1999-2000.
[PubMed] [DOI][Cited in This Article: ]
Umeda M, Kobayashi H, Takeuchi Y, Hayashi J, Morotome-Hayashi Y, Yano K, Aoki A, Ohkusa T, Ishikawa I. High prevalence of Helicobacter pylori detected by PCR in the oral cavities of periodontitis patients.J Periodontol. 2003;74:129-134.
[PubMed] [DOI][Cited in This Article: ]
Adler I, Denninghoff VC, Alvarez MI, Avagnina A, Yoshida R, Elsner B. Helicobacter pylori associated with glossitis and halitosis.Helicobacter. 2005;10:312-317.
[PubMed] [DOI][Cited in This Article: ]
Okuda K, Kimizuka R, Katakura A, Nakagawa T, Ishihara K. Ecological and immunopathological implications of oral bacteria in Helicobacter pylori-infected disease.J Periodontol. 2003;74:123-128.
[PubMed] [DOI][Cited in This Article: ]
